SAN DIEGO—(BUSINESS WIRE)—Nov. 26, 2018—ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical companyfocused on the development and commercialization of innovative medicinesto address unmet medical needs in central nervous system (CNS)disorders, today announced that it intends to offer and sell, in anunderwritten public offering and subject to market and other conditions,$200,000,000 of its common stock. There can be no assurance as towhether or when the offering may be completed, or as to the actual sizeor terms of the offering.
BofA Merrill Lynch, J.P. Morgan Securities LLC and Goldman Sachs & Co.LLC are acting as the joint book-running managers for the offering.ACADIA intends to grant the underwriters a 30-day option to purchase upto an additional $30,000,000 of its common stock.
The shares of common stock described above are being offered by ACADIApursuant to a shelf registration statement filed by ACADIA with theSecurities and Exchange Commission (SEC) that became automaticallyeffective on November 26, 2018. A preliminary prospectus supplementrelated to the offering will be filed with the SEC and will be availableon the SEC’s website located at http://www.sec.gov.Copies of the preliminary prospectus supplement and the accompanyingprospectus related to this offering, when available, may be obtainedfrom BofA Merrill Lynch, NC1-004-03-43, 200 North College Street, 3rdFloor, Charlotte, NC 28255-0001, Attn: Prospectus Department, Email: dg.prospectus_requests@baml.com,or from J.P. Morgan Securities LLC, Attention: Broadridge FinancialSolutions, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at(866) 803-9204, or by email to: prospectus-eq_fi@jpmchase.com,or from Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200West Street, New York, NY 10282, or by telephone at (866) 471-2526, orby email to: prospectus-ny@nyemail.gs.com.
This press release shall not constitute an offer to sell or thesolicitation of an offer to buy these securities, nor shall there be anysale of these securities in any state or other jurisdiction in whichsuch offer, solicitation or sale would be unlawful prior to theregistration or qualification under the securities laws of any suchstate or other jurisdiction.
About ACADIA Pharmaceuticals
ACADIA is a biopharmaceuticalcompany focused on the development and commercialization of innovativemedicines to address unmet medical needs in central nervous systemdisorders. ACADIA has developed and is commercializing the first andonly medicine approved for the treatment of hallucinations and delusionsassociated with Parkinson’s disease psychosis. In addition, ACADIA hasongoing clinical development efforts in additional areas withsignificant unmet need, including dementia-related psychosis,schizophrenia inadequate response, schizophrenia-negative symptoms,major depressive disorder, and Rett syndrome.
Forward-Looking Statements
Statements in this press releasethat are not strictly historical in nature are forward-lookingstatements. These statements include but are not limited to statementsrelated to the proposed offering of common stock by ACADIA. Thesestatements are only predictions based on current information andexpectations and involve a number of risks and uncertainties. Actualevents or results may differ materially from those projected in any ofsuch statements due to various factors, including market risks anduncertainties and the satisfaction of customary closing conditions foran offering of securities. For a discussion of these and other factors,please refer to ACADIA’s annual report on Form 10-K for the year endedDecember 31, 2017 as well as ACADIA’s subsequent filings with theSecurities and Exchange Commission. You are cautioned not to place unduereliance on these forward-looking statements, which speak only as of thedate hereof. This caution is made under the safe harbor provisions ofthe Private Securities Litigation Reform Act of 1995. Allforward-looking statements are qualified in their entirety by thiscautionary statement and ACADIA undertakes no obligation to revise orupdate this press release to reflect events or circumstances after thedate hereof, except as required by law.
Source: ACADIA Pharmaceuticals Inc.
Investor Contact:
ACADIA Pharmaceuticals Inc.
ElenaRidloff, CFA
(858) 558-2871
ir@acadia-pharm.com
Media Contact:
ACADIA Pharmaceuticals Inc.
MaurissaMessier
(858) 768-6068
media@acadia-pharm.com